This clinical trial focuses on studying Alzheimer’s Disease, a condition that affects memory and cognitive function. The study will test a new medication called VHB937, which is given as a concentrate for solution for infusion through intravenous administration. The purpose is to evaluate how well this new treatment works on thinking ability and daily functioning in people with early stages of the disease.
The study will compare VHB937 with placebo over a period of 72 weeks, followed by an extension period. During the study, participants will receive regular infusions of either the study medication or placebo. The study will include people who have early Alzheimer’s Disease, including those with Mild Cognitive Impairment due to Alzheimer’s.
Throughout the study, doctors will monitor changes in participants’ ability to think and perform daily activities. They will use various tests to measure memory and thinking skills, including the Clinical Dementia Rating scale. Participants will undergo regular health checks, including brain MRI scans, to ensure safety. Some participants may continue taking their regular Alzheimer’s medications during the study if they were already using them before joining.
Czechia 
France 
Germany 
Italy 
Poland 
Spain 
Sweden 
The Netherlands 
